AMSTERDAM—Philips Respironics announced the discontinuation of 19 sleep and respiratory products in the United States with a shift in focus to the sale of consumables and accessories, including masks.
The U.S. Food and Drug Administration (FDA) is warning patients and health care providers to carefully monitor Philips DreamStation 2 CPAP devices for signs of overheating.
CAMBRIDGE, Massachusetts—Royal Philips, a global health technology company, announced it earned a spot on Forbes’ 2023 “America’s Best Employers for Women” list. This is the third time Philips has appeared in the ranking that includes only 400 organizations across the country, and it has climbed more than 250 positions compared to its placement on last year’s list. Philips was also listed as one of the top three companies in the Health Care Equipment & Services category.
Philips Respironics provided the latest results and conclusions on the comprehensive test and research program to assess potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in specific sleep therapy and ventilator devices under the voluntary June 2021 recall notification/field safety notice.*
WASHINGTON, D.C.—More than a year-and-a-half after Philips announced the voluntary recall of 3 million to 4 million of its sleep apnea devices and ventilators, the U.S.
PITTSBURGH & CEDAR RAPIDS, Iowa (September 23, 2022)—Philips RS North America LLC, formerly known as Respironics, Inc., a nationwide manufacturer of sleep and respiratory durable medical equipment (DME), has agreed to pay more than $1.2 million to settle allegations that it unlawfully induced referrals for its equipment in violation of the False Claims Act and Anti-Kickback Statute.
AMSTERDAM (August 18, 2022)—Royal Philips, a global provider of health technology, announced that Roy Jakobs is proposed to succeed Frans van Houten as president and chief executive officer, effective Oct. 15, 2022.
CAMBRIDGE, Mass. (July 5, 2022)—Royal Philips, a global provider of health technology, announced the company has joined an initiative created by the Department of Health and Human Services (HHS), in partnership with the White House, to address climate action through the reduction of greenhouse gas emissions.
BIRMINGHAM, Alabama (April 25, 2022)—Philips expects to produce and ship more than 90% of new or repaired devices to consumers to replace their recalled CPAP, BiPAP and mechanical ventilators by the end of 2022, the company said Monday.
BIRMINGHAM, Alabama (January 27, 2022)—The Food and Drug Administration has expanded Philips Respironics’ product recall, adding the Trilogy Evo ventilator and muffler repair kits to the list—and declared it a level 1 recall, the most severe.
BIRMINGHAM, Alabama (August 19, 2021)—A surge in demand for sleep and respiratory devices in the wake of a Philips Respironics recall has created “an unprecedented increase in demand” for Resmed devices, the company’s CEO said—but supply chain and freight limitations are making it hard for the company to keep up. Nonetheless, the company could realize $300 million-$350 million in unplanned additional revenue in fiscal year 2022, he said.
PHOENIX, Arizona (July 14, 2021)—Home medical equipment providers may need to wait as long as a year before the situation is back to normal on Philips Respironics CPAP devices, which have been put on hold due to a nationwide recall, according to the American Association for Homecare.
AMSTERDAM (June 14, 2021)—On Monday, Philips announced it is voluntarily recalling nearly 4 million CPAP machines and noninvasive ventilators to ensure patient safety in consultation with regulatory agencies. Corrective actions include the deployment of updated instructions for use and a repair and replacement program for affected devices.
AMSTERDAM (March 10, 2021)—Royal Philips, a global provider of health technology, announced the findings of its sixth annual sleep survey in a report titled “Seeking Solutions: How COVID-19 Changed Sleep Around the World.”
AMSTERDAM (November 17, 2020)—Royal Philips, a global provider of health technology, today announced findings from its first ever World COPD Day survey ahead of the awareness day on November 18. Philips surveyed more than 4,000 adults in China, India, Russia and the U.S. to gather insights on global awareness of respiratory conditions, such as chronic obstructive pulmonary disease (COPD), and how the COVID-19 pandemic has influenced overall perceptions of respiratory health.
AMSTERDAM (September 1, 2020)—Royal Philips, a provider of health technology, announced that it has received notice from the U.S. Department of Health and Human Services (HHS) of the partial termination of the April 2020 contract to deliver 43,000 bundled EV300 ventilator configurations to HHS through December 2020.
AMSTERDAM (July 24, 2020)—Royal Philips, a global provider of health technology, announced the publication of a peer-reviewed, retrospective outcomes study demonstrating that, in the first year of use, high frequency chest wall oscillation therapy (HFCWO) reduced the rate of chronic respiratory patient hospitalization by more than 50%. According to the study, antibiotic use also decreased significantly.
AMSTERDAM (July 9, 2020)—Royal Philips, a provider of health technology, announced the launch of the Philips Respironics Mask Selector, a clinically validated, 3D facial scanning solution that helps providers to fit 9 out of 10 patients with the right mask from the start. The proprietary Mask Selector algorithm offers a novel solution in the shift toward digitization of health care, helping to improve business efficiencies by reducing costs associated with fitting time and mask waste.
AMSTERDAM (July 9, 2020)— Royal Philips, a provider of health technology, announced it has formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its BioSticker medical device into Philips’ remote patient monitoring (RPM) offering to help monitor at-risk patients from the hospital into the home.
